Loading companies…
NT
NovaGo Therapeutics
Switzerland · Biotech
NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury.
Product and customers
NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury.
Its lead anti-Nogo-A antibody targets a protein that inhibits nerve-fibre regeneration and neuroplasticity. The intended treatment seeks to improve functional recovery; the lead program is moving toward a 120-patient proof-of-concept study in acute spinal-cord injury.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | CHF 24M | Neurimmune — LeadPureos Bioventures — Lead |
Investors
NeurimmuneLed Series BPureos BioventuresLed Series BCoverage
Sep 2, 2026NovaGo Therapeutics · Series BSimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed